Back to search

Article

Novel and Reported Compensatory Mutations in <i>rpoABC</i> Associate Specifically with Predominant <i>Mycobacterium tuberculosis</i> Rifampicin Resistance Marker <i>rpoB</i> :S450L

2022-02-24

Abstract excerpt

<h4>Background</h4> Rifampicin (RIF) is a key first-line drug used to treat tuberculosis, a pulmonary disease caused by Mycobacterium tuberculosis . However antibiotic resistance to RIF is prevalent despite an apparent fitness cost. RIF resistance is primarily caused by mutations in the RIF resistance determining region in the rpoB gene, at the cost of slower growth in rich media. Compensatory mutations in the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3327eb6a-ffd8-5844-856d-ee77900139a1
DOI
10.1101/2022.02.22.481565
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel and Reported Compensatory Mutations in <i>rpoABC</i> Associate Specifically with Predominant <i>Mycobacterium tuberculosis</i> Rifampicin Resistance Marker <i>rpoB</i> :S450LDOI 10.1101/2022.02.22.481565
Select a neighboring publication to make it the new centre.